Medline Inc. (MDLN) is listed on NASDAQ and operates in the Medical - Instruments & Supplies industry (Healthcare sector).
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. It operates through two segments: Medline Brand and Supply Chain Solutions. The Medline Brand segment procures and manufactures products from three product categories include surgical solutions, front line care, and laboratory and diagnostics. Its front line care offers med-surg products for patient-facing needs, including wound care products, exam gloves, skin care and incontinence products, environment cleaning supplies, textiles, hand sanitizer, durable medical equipment, patient plastics, and decolonization and infection control products. Its surgical solutions provide operating room and perioperative environment product solutions, including surgical procedure trays, drapes and gowns, personal protective equipment, sterile wraps, surgical instruments, surgeon's gloves, procedure kits, and orthopedic implants. Its laboratory and diagnostics offer laboratory and diagnostic product solutions, including point of care testing, analyzers and instrumentation, lab and diagnostic consumables, diagnostic instruments, vital signs monitors, and anatomic pathology and phlebotomy products. It provides its products to domestic and international consumers. The Supply Chain Solutions segment procures and distributes a variety of third-party products from national brands. It provides logistic...
| Rating | Analysts |
|---|---|
| Strong Buy | 0 |
| Buy | 10 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
Medline Inc., founded in 1966 and headquartered in Northfield, Illinois, operates in the healthcare sector, specifically within the medical instruments and supplies industry. The company manufactures and distributes medical-surgical products to hospitals, surgery centers, physician offices, post-acute facilities, and nursing homes both in the United States and internationally. Medline operates through two main segments: Medline Brand and Supply Chain Solutions.
The Medline Brand segment focuses on procuring and manufacturing products across three categories: surgical solutions, frontline care, and laboratory and diagnostics. Surgical solutions include items for operating rooms and perioperative environments, such as procedure trays, drapes, gowns, and surgical instruments. Frontline care products address patient needs with wound care, exam gloves, skin care, and infection control products. The laboratory and diagnostics category provides solutions for point-of-care testing and diagnostic instruments.
The Supply Chain Solutions segment distributes third-party products from national brands and offers logistics and supply chain optimization services. These services include consulting, warehouse management, packaging, third-party logistics, inventory management, and route planning, catering to both domestic and international clients.
Over the past three fiscal years, the company has demonstrated robust revenue growth, with a consistent increase at a compound annual growth rate (CAGR) of 10.6%, rising from $23.23 billion in 2023 to $28.43 billion in 2025. This growth has been accompanied by an improvement in profitability metrics. The gross margin expanded by 4.0 percentage points from 22.5% to 26.4%, while the operating margin showed an inconsistent yet positive trend, increasing by 1.6 percentage points to 7.8%. Net margin also improved by 3.1 percentage points, reaching 4.1% by 2025. Earnings per share (EPS) exhibited significant volatility but ultimately increased from $0.30 to $1.43, reflecting a remarkable CAGR of 118.3%. On the cash flow front, free cash flow (FCF) consistently increased, with a CAGR of 11.6%, reaching $1.74 billion in 2025, indicating strong cash generation capabilities. The company's capital efficiency improved, as evidenced by a consistent increase in asset turnover, reaching 0.76, and a return on invested capital (ROIC) that rose to 9.6%. Despite an increase in net debt from $15.24 billion to $10.62 billion, the company's liquidity remains strong, with a current ratio of 4.29 and a quick ratio of 2.37. However, the share count increased by 3.2%, slightly diluting per-share gains. Overall, the company has shown a solid performance with improved profitability and cash generation, although the increase in share count presents a minor challenge to per-share value growth.
Medline Inc. (MDLN) recently reported its first-quarter 2026 financial results, revealing an 8% decline in revenue to $239 million from $322 million in the same period last year. This decrease was primarily attributed to higher costs of goods sold, including tariffs, and increased operating expenses linked to new customer growth and an employee bonus related to the company's IPO. Adjusted EBITDA fell by 10.6% to $776 million. Despite these challenges, Medline raised its full-year 2026 organic sales guidance. In strategic developments, Medline announced a significant partnership with Symbotic to pilot AI robotics technology in 2027, enhancing its distribution capabilities. Additionally, the company launched Pick Pack Pro™, a custom product fulfillment technology aimed at improving order accuracy and delivery times for health plan providers. On the regulatory front, Medline received an FDA warning for quality issues related to its angiographic syringes. Institutional interest in Medline remains strong, with notable investments from Baillie Gifford & Co. and other firms during the fourth quarter. These developments highlight Medline's ongoing efforts to innovate and expand, despite facing operational and regulatory challenges.